Cosmos Health heads into its May 14 earnings print with one signal dominating the setup: a CEO who has spent months buying his own stock at prices well above where it trades today.
Chairman and CEO Grigorios Siokas added roughly 2.7 million net shares in the 90 days through mid-February, deploying around $1.3 million of personal capital across repeated open-market purchases. The buying ran from January through February at prices between $0.37 and $0.54 — all above the current close of $0.31. That persistence is notable. This was not a single block purchase. Siokas returned to the market at least ten times in two months, averaging in across a declining tape. He now holds 17.5% of shares outstanding. A second large holder, Andreas Bovopoulos, reported adding nearly 2.7 million shares as recently as April 24, lifting his stake to 8.2%.
Short interest tells a quiet story heading into the print. At just 0.84% of the free float, there is no meaningful short-side pressure to unwind. Short positions have actually collapsed — down 58% over the past week and more than 27% in a single session on May 8 — after a mid-April spike that pushed the figure briefly above 1.8 million shares. The borrow market is loose: cost to borrow runs at roughly 1.2% annually, and availability is ample, well off the 52-week tightness seen in April. The ORTEX short score has eased to 37.4 from above 45 ten days ago, reflecting the retreat in bearish positioning.
One standout factor score is worth noting: the company ranks in the 98th percentile on EPS surprise, meaning it has a strong track record of beating analyst estimates relative to peers. That sets a high bar for the bull case — past beats have driven sharp single-session moves. The two most recent earnings events produced 1-day gains of 6% and 22% respectively, with the April 15 release the larger of the two. The November 2025 print was the exception, delivering a 3.7% drop. Analyst coverage appears minimal and any available price targets are too dated to be meaningful.
The May 14 print is therefore less a test of short-side conviction — there is almost none — and more a test of whether the CEO's sustained personal buying reflects visibility into results that the market has not yet priced at $0.31.
See the live data behind this article on ORTEX.
Open COSM on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
